The recent approval of a new schizophrenia drug opens the door for newer, safer, and more efficacious treatment options without the unwanted side-effects.
With the the psychedelic field dynamic and rapidly changing, Monash’s pioneering Clinical Psychedelic Lab has a vision to make a meaningful difference in mental healthcare.
Despite the thalidomide experience, research into the effects of medication during pregnancy is inadequate, including in cases where pregnant women need to continue their medication.
This week, Monash University's “What Happens Next?” podcast investigates how making reproductive healthcare inaccessible hurts us all.
A class of drugs developed to treat type 2 diabetes and obesity is in short supply, sparking debate about who should be prioritised for access.
As Alzheimer’s cases grow, scientists have been deep in debate over its causes. Now, with treatments are on the horizon, the new race is to ready the health system.
It’s almost comically hypocritical to argue that the Therapeutic Goods Administration needs to ‘loosen up’ in the context of the COVID-19 pandemic.
The federal government’s Rapid Antigen Test policy is a disaster by any measure. It should own up to its policy failure and try to improve the situation as soon as possible.
For only the second time in 60 years, a drug has been approved for the treatment of lupus, a debilitating form of rheumatic disease.
Since COVID-19's emergence, soaps and sanitisers are ubiquitous, but researchers are warning that the antibacterial additives they contain are dangerous to our health.
With the COVID-19 landscape changing daily, an Australian team of researchers and clinicians has come together to deliver up-to-the-minute, evidence-based guidance for the care of people with the disease.
Dummy text
